Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03BSK
|
|||
| Former ID |
DIB010870
|
|||
| Drug Name |
URC102
|
|||
| Indication | Gout [ICD-11: FA25; ICD-10: M10] | Phase 2 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Urate anion exchanger 1 (URAT1) | Target Info | Inhibitor | [2] |
| WikiPathways | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02290210) Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.